Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075523 | 0.87 | KCNH2 (0.44) | TACR1SLC6A4KCNH2GRM2DRD2 | |
| SCHEMBL21075678 | 0.87 | TACR1 (0.43) | TACR1SLC6A4KCNH2GRM2DRD2 | |
| SCHEMBL21075333 | 0.86 | KCNH2 (0.44) | TACR1SLC6A4KCNH2HPGDKMT2A | |
| SCHEMBL21075802 | 0.84 | TACR1 (0.49) | TACR1SLC6A4KCNH2KMT2AHRH3 | |
| SCHEMBL16770692 | 0.77 | TACR1 (0.46) | TACR1SLC6A4KCNH2HPGDKMT2A | |
| SCHEMBL17061916 | 0.74 | TACR1 (0.46) | TACR1SLC6A4KCNH2HPGDKMT2A | |
| SCHEMBL17828179 | 0.73 | ACHE (0.49) | DRD2DRD4ACHEHRH3 | |
| SCHEMBL17069228 | 0.73 | TACR1 (0.44) | TACR1SLC6A4KCNH2CNR2ACHE | |
| SCHEMBL4021955 | 0.73 | TACR1 (0.45) | TACR1SLC6A4KCNH2HPGDGRM2 | |
| SCHEMBL4023227 | 0.73 | KCNH2 (0.45) | TACR1SLC6A4KCNH2HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | TACR1 307/4885SLC6A4 1914/4885KCNH2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.